Lupin is currently trading at Rs. 636.20, up by 8.35 points or 1.33% from its previous closing of Rs. 627.85 on the BSE.
The scrip opened at Rs. 632.80 and has touched a high and low of Rs. 638.65 and Rs. 631.00 respectively. So far 49,000 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 633.10 on 22-Mar-2013 and a 52 week low of Rs. 485.00 on 26-Mar-2012.
Last one week high and low of the scrip stood at Rs. 633.10 and Rs. 606.60 respectively. The current market cap of the company is Rs. 28,461 crore.
The promoters holding in the company stood at 46.85% while Institutions and Non-Institutions held 43.4% and 9.75% respectively.
Pharma major, Lupin’s subsidiary - Lupin Pharmaceuticals Inc has received final approval for its Valsartan and Hydrochlorothiazide Tablets USP, 80 mg/12.5 mg, 160 mg/12.5 mg, 160 mg/25 mg, 320 mg/12.5 mg and 320 mg/25 mg from the United States Food and Drugs Administration (US FDA) to market a generic version of Novartis Pharmaceuticals Corp.’s (Novartis) Diovan HCT Tablets, 80 mg/12.5 mg, 160 mg/12.5 mg, 160 mg/25 mg, 320 mg/12.5 mg and 320 mg/25 mg, respectively. The company has already commenced shipping the product.
Lupin’s Valsartan and Hydrochlorothiazide Tablets USP is indicated for the treatment of hypertension, to lower blood pressure in patients not adequately controlled with monotherapy or as initial therapy in patients who are likely to need multiple drugs to achieve their blood pressure goals. Valsartan and Hydrochlorothiazide Tablets USP, 80/12.5 mg, 160/12.5 mg, 160/25 mg, 320/12.5 mg and 320/25 mg had annual US sales of approximately $1.7 billion (IMS MAT Sept 2012 sales).
Lupin is the 5th largest and fastest growing generics player in the US (5.1% market share by prescriptions, IMS Health) and the 3rd largest Indian pharmaceutical company by sales. The company is also the fastest growing top 10 generic pharmaceutical players in Japan and South Africa (IMS).
